57 related articles for article (PubMed ID: 12747756)
1. Expression of cancer-testis genes in human hepatocellular carcinomas.
Luo G; Huang S; Xie X; Stockert E; Chen YT; Kubuschok B; Pfreundschuh M
Cancer Immun; 2002 Sep; 2():11. PubMed ID: 12747756
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the antibody repertoire of lymphoma patients.
Huang S; Preuss KD; Xie X; Regitz E; Pfreundschuh M
Cancer Immunol Immunother; 2002 Dec; 51(11-12):655-62. PubMed ID: 12439611
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.
Liang J; Ding T; Guo ZW; Yu XJ; Hu YZ; Zheng L; Xu J
Br J Cancer; 2013 Aug; 109(4):1031-9. PubMed ID: 23868000
[TBL] [Abstract][Full Text] [Related]
4. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Halwani AA
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma.
Ge YY; Zhang QM; Liu C; Zeng X; Nong WX; Chen F; Bi SQ; Guo WW; Luo B; Xie XX
Am J Transl Res; 2021; 13(7):7591-7609. PubMed ID: 34377237
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma.
Craig AJ; Garcia-Lezana T; Ruiz de Galarreta M; Villacorta-Martin C; Kozlova EG; Martins-Filho SN; von Felden J; Ahsen ME; Bresnahan E; Hernandez-Meza G; Labgaa I; D'Avola D; Schwartz M; Llovet JM; Sia D; Thung S; Losic B; Lujambio A; Villanueva A
PLoS Genet; 2021 Jun; 17(6):e1009589. PubMed ID: 34166362
[TBL] [Abstract][Full Text] [Related]
7. Synaptonemal complex proteins modulate the level of genome integrity in cancers.
Hosoya N; Miyagawa K
Cancer Sci; 2021 Mar; 112(3):989-996. PubMed ID: 33382503
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model.
Safavi A; Kefayat A; Mahdevar E; Ghahremani F; Nezafat N; Modarressi MH
Hum Vaccin Immunother; 2021 Jan; 17(1):22-34. PubMed ID: 32497486
[TBL] [Abstract][Full Text] [Related]
9. The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis.
Gantchev J; Martínez Villarreal A; Gunn S; Zetka M; Ødum N; Litvinov IV
Cell Cycle; 2020 Apr; 19(8):837-854. PubMed ID: 32223693
[TBL] [Abstract][Full Text] [Related]
10. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of hepatocellular carcinoma.
Sangro B; Palmer D; Melero I
Hepat Oncol; 2014 Oct; 1(4):433-446. PubMed ID: 30190978
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
13. Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability.
Nielsen AY; Gjerstorff MF
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27275820
[TBL] [Abstract][Full Text] [Related]
14. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
15. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.
Sideras K; Bots SJ; Biermann K; Sprengers D; Polak WG; IJzermans JN; de Man RA; Pan Q; Sleijfer S; Bruno MJ; Kwekkeboom J
Br J Cancer; 2015 Jun; 112(12):1911-20. PubMed ID: 26057582
[TBL] [Abstract][Full Text] [Related]
16. High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma.
He SJ; Gu YY; Yu L; Luo B; Fan R; Lin WZ; Lan XW; Lin YD; Zhang QM; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2014; 7(5):2350-60. PubMed ID: 24966945
[TBL] [Abstract][Full Text] [Related]
17. HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma.
Aref AM; Hoa NT; Ge L; Agrawal A; Dacosta-Iyer M; Lambrecht N; Ouyang Y; Cornforth AN; Jadus MR
Onco Targets Ther; 2014; 7():1061-70. PubMed ID: 24966688
[TBL] [Abstract][Full Text] [Related]
18. Advances in the study of HLA-restricted epitope vaccines.
Zhao L; Zhang M; Cong H
Hum Vaccin Immunother; 2013 Dec; 9(12):2566-77. PubMed ID: 23955319
[TBL] [Abstract][Full Text] [Related]
19. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Neumann F; Kaddu-Mulindwa D; Widmann T; Preuss KD; Held G; Zwick C; Roemer K; Pfreundschuh M; Kubuschok B
Cancer Immunol Immunother; 2013 Jul; 62(7):1211-22. PubMed ID: 23619976
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
